Peptides which mimic candida carbohydrate epitopes and their use in a vaccine

• US 6,309,642 B1
• Filed: 05/13/1998
• Issued: 10/30/2001
• Est. Priority Date: 04/28/1997
• Status: Expired due to Fees

• Current Assignee: Montana Inc.
• Original Assignee: Research and Development Institute, Inc.
• Inventors: Glee, Pati M., Cutler, Jim E.
• Primary Examiner(s): DUFFY, PATRICIA ANN
• Application Number:
  US09/076,883
• Time in Patent Office: 1,266 Days
• Field of Search: 424/184.1, 424/185.1, 424/274.1, 436/819, 514/44, 514/15, 514/2, 530/328, 530/300
• US Class Current: 424/185.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0002 Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07K 14/40 from Candida
• CPC Class Codes: C07K 16/14 against material from fungi, algea or lichens
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids
• CPC Class Codes: C07K 7/08 having 12 to 20 amino acids gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68

Abstract

A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannan of C. albicans, peptide mimotopes of phosphomannan epitopes, or polynucleotides encoding the peptide mimotopes. Monoclonal antibodies for use in passive immunization against candida infections are also provided.

Claims

1. A vaccine for the treatment of candidiasis comprising a pharmaceutically effective amount of a protective peptide mimitope, wherein the peptide mimitope binds to an antibody that binds to the same epitope as monoclonal antibody B6.1, American Type Culture Collection Accession Number HB11925.

2. The vaccine of claim 1, wherein the peptide mimitope comprises residues one through nine of SEQ ID NO:

2.

3. The vaccine of claim 1, wherein the peptide mimitope consists of residues one through nine of SEQ ID NO:

2.

4. The vaccine of claim 1, wherein the peptide mimitope comprises residues one through nine of SEQ ID NO:

3.

5. The vaccine of claim 1, wherein the peptide mimitope consists of residues one through nine of SEQ ID NO:

3.

6. The vaccine of claim 1, wherein the peptide mimitope comprises residues one through nine of SEQ ID NO:

4.

7. The vaccine of claim 1, wherein the peptide mimitope consists of residues one through nine of SEQ ID NO:

4.

8. The vaccine of claim 1, wherein the peptide mimitope comprises residues one through nine of SEQ ID NO:

5.

9. The vaccine of claim 1, wherein the peptide mnmuntope consists of residues one through nine of SEQ ID NO:

5.

10. The vaccine of claim 1, wherein the peptide mimitope comprises residues one through nine of SEQ ID NO:

6.

11. The vaccine of claim 1, wherein the peptide mimitope consists of residues one through nine of SEQ ID NO:

6.

12. The vaccine of claim 1, wherein the peptide mimitope comprises SEQ ID NO:

8.

13. The vaccine of claim 1, wherein the peptide mimitope consists of SEQ ID NO:

8.

14. The vaccine of any of claims 1 to 13, further comprising a pharmaceutically acceptable carrier.

15. A method for immunization against candidiasis comprising administering a therapeutically effective amount of the vaccine of any of claims 1 to 13.

16. A method for immunization against candidiasis comprising administering a therapeutically effective amount of the vaccine of claim 14.